Owlet Inc. (OWLT)
NYSE NYSE Primary 
Owlet's Data Flywheel Grows: Can AI Boost Lifetime Value?
OWLT's growing data flywheel and AI plans aim to deepen engagement, boost subscriptions, and extend customer value.
Recent Price Trend in Owlet (OWLT) is Your Friend, Here's Why
Owlet (OWLT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Owlet (OWLT) Is a Great Choice for 'Trend' Investors, Here's Why
Owlet (OWLT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why Momentum in Owlet (OWLT) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Owlet (OWLT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes Owlet (OWLT) a New Strong Buy Stock
Owlet (OWLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Owlet, Inc. (OWLT) Q3 2025 Earnings Call Transcript
Owlet, Inc. ( OWLT ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay Gentzkow - Vice President of Investor Relations Jonathan Harris - CEO & President Amanda Crawford - Chief Financial Officer Conference Call Participants Lucas Romanski - TD Cowen, Research Division Owen Rickert - Northland Capital Markets, Research Division Presentation Operator Good afternoon. Thank you for attending the Owlet Q3 '25 Earnings Conference Call.
Owlet, Inc. (OWLT) Surpasses Q3 Earnings and Revenue Estimates
Owlet, Inc. (OWLT) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.03 per share a year ago.
Owlet (OWLT) Surges 17.9%: Is This an Indication of Further Gains?
Owlet (OWLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Owlet Keeps Delivering Growth While The Market Sleeps
Owlet, Inc. remains a buy as it evolves into a comprehensive pediatric health platform and consistently beats and raises revenue guidance. OWLT demonstrates strong revenue growth, improving operating leverage, and expanding high-margin subscription offerings, despite ongoing operating losses and tariff headwinds. Key growth catalysts include Owlet 360 subscriber expansion, BabySat healthcare partnerships, and a telehealth pilot, with international growth still in early stages.
Owlet, Inc.(OWLT) Q2 2025 Earnings Call Transcript
Owlet, Inc.(NYSE:OWLT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Amanda Twede Crawford - Chief Financial Officer Jay Gentzkow - Vice President of Investor Relations Jonathan Harris - President Kurt Workman - Co-Founder, CEO & Director Conference Call Participants Alex Joseph Fuhrman - Lucid Capital Markets, LLC, Research Division Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division Boris Peaker - Unidentified Company Charles Rhyee - TD Cowen, Research Division Owen Ray Rickert - Northland Capital Markets, Research Division Operator Good afternoon. Thank you for attending today's Owlet Q2 '25 Earnings Conference Call.
Owlet, Inc. (OWLT) Reports Q2 Loss, Beats Revenue Estimates
Owlet, Inc. (OWLT) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to break-even earnings per share a year ago.
Owlet: Back From Purgatory, Market Underappreciates Turnaround
Owlet has rebounded from FDA-related setbacks, regaining approval and showing strong revenue growth, with new revenue highs and improved margins in 2024. Key growth drivers include FDA-cleared products, the new Owlet 360 subscription, international expansion, and healthcare partnerships, all supporting revenue. Risks remain with high SG&A costs, customer concentration, dilution, and regulatory uncertainties, but profitability is expected as the company scales.
